FDA approval for Augment is expected sometime in the next 6 months. Augment received a favorable FDA Panel vote last week. BioMimetic CEO and BioMimetic VP / Regulatory & Clinical Affairs bought shares in the open market the past few days, so they must also feel Augment will get FDA approval. JPM has price target of $17 for BMTI. I think with FDA approval, $35+ is possible, imo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.